Long‐term function of a novel autologous transcatheter pulmonary heart valve implant in an adult animal model
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.30992 ↗At a glance
Journal article in Catheterization and Cardiovascular Interventions, 2024. Written by Jonathan Kiekenap and 7 co-authors. Institution: DHZC (Deutsches Herzzentrum der Charité), Charité - University Medicine, Berlin, Germany. Major MEDLINE topics: Pulmonary Valve, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation. Cited 2 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: German Federal Ministry for Economic Affairs and Climate Action.
Abstract (original language)
Background
Current heart valve implants entail major disadvantages in the treatment for younger patients or those with congenital heart defects.
Aim
Evaluation of novel transcatheter pulmonary valve implant made from autologous pericardium with natural crosslinking agent in an in vitro setup and in vivo animal model Methods Valves were tested in a pulse duplicator according to ISO‐standard 5840. For in vivo studies computer tomography was performed to measure sheep's native pulmonary valve dimensions. Pericardium was harvested by thoracotomy, personalized implants were manufactured and deployed in pulmonary valve position of the same sheep. Every 3 months implant functionality was evaluated by intracardiac echocardiography, intracardiac pressure measurements and cardiac magnetic resonance imaging (cMRI). Implants were explanted for macroscopic and histological examination.
Results
In vitro experiments showed compliance with regulatory requirements in terms of valve opening and insufficiency. Five sheep successfully received an autologous valve implant. Two animals had to be euthanized due to trauma sustained in the stable. Long‐term valve function was excellent in three out of four animals with median implant cMRI regurgitation fraction of 9% ( n = 4) at 3 months, 8% ( n = 3) at 6, 8% ( n = 3) at 9, 12% ( n = 3) at 13, 8% ( n = 2) at 17% and 8% ( n = 2) at 20.5 months after implantation. Despite good adherence to neighboring tissue and endothelization, histological assessment revealed some signs of degeneration.
Conclusion
Transcatheter pulmonary valve implants showed promising function for up to 20.5 months encouraging research to further improve this approach.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- DHZC (Deutsches Herzzentrum der Charité), Charité - University Medicine, Berlin, Germany.
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
- BIH (Berlin Institute of Health), Berlin, Germany.
- BCRT (BIH Center of Regenerative Therapies), Berlin, Germany.
ORCID profiles: Jonathan Kiekenap, Boris Schmitt
Funding
- German Federal Ministry for Economic Affairs and Climate Action
Cite
APA
Kiekenap, J., Sun, X., Hao, Y., Steitz, M., Breitenstein-Attach, A., Emeis, J., Berger, F., & Schmitt, B. (2024). Long‐term function of a novel autologous transcatheter pulmonary heart valve implant in an adult animal model. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30992
Vancouver
Kiekenap J, Sun X, Hao Y, Steitz M, Breitenstein-Attach A, Emeis J, et al. Long‐term function of a novel autologous transcatheter pulmonary heart valve implant in an adult animal model. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.30992
BibTeX
@article{Kiekenap2024,
author = {Kiekenap, Jonathan and Sun, Xiaolin and Hao, Yimeng and Steitz, Marvin and Breitenstein-Attach, Alexander and Emeis, Jasper and Berger, Felix and Schmitt, Boris},
title = {Long‐term function of a novel autologous transcatheter pulmonary heart valve implant in an adult animal model},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.30992}
}
EUVIMED